Topic: drug sales

Amarin has sidelined its sales team for two weeks in a move that could have an immediate effect on sales of fish-oil derivative Vascepa.

GSK and Alcon have pulled off prescription-to-OTC switches in hopes of giving aging brands Voltaren and Pataday a boost.

Humira's best days may be past, but AbbVie could one day see $20 billion in combined sales for follow-ups Rinvoq and Skyrizi, CEO Rick Gonzalez said.

Alexion is facing a competitor to its blockbuster Soliris amid a switching campaign to a follow-up drug. But analysts so far aren't concerned.

Weeks after netting a label expansion with blockbuster potential, fish-oil derivative Vascepa is lifting Amarin to Street-beating sales.

Already facing U.S. copycats to its oncology trio, Roche can take solace in a middling sales impact so far. Could a new challenger change that?

With AbbVie's two most recent launches outperforming expectations, investors could be looking at a steal with an Allergan merger looming.

Teva is riding high after a strong launch for Austedo. But is "tenfold" patient growth in one of its indications possible? Analysts aren't so sure.

With two oncology blockbuster already facing U.S. biosims, Roche is facing a tough road ahead. Now, a third Roche cancer med is in the firing line.